XML 45 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated statements of operations:
202220212020
Net product revenue$25,462.8 $25,957.9 $22,694.8 
Collaboration and other revenue(1)
3,078.6 2,360.5 1,845.0 
Revenue$28,541.4 $28,318.4 $24,539.8 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively.
The following table summarizes revenue by product:
U.S.Outside U.S.
202220212020202220212020
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$5,688.8 $4,914.4 $3,835.9 $1,750.9 $1,557.6 $1,232.2 
Jardiance(1)
1,194.5 807.3 620.8 871.5 683.5 533.0 
Humalog® (2)
1,191.9 1,320.7 1,485.6 868.7 1,132.3 1,140.3 
Humulin®
730.2 832.9 866.4 289.2 389.6 393.2 
Basaglar®
470.7 588.3 842.3 289.7 304.2 282.1 
Mounjaro®
366.6 — — 115.9 — — 
Other diabetes268.4 255.7 258.1 367.8 401.6 344.5 
Total diabetes9,911.1 8,719.3 7,909.1 4,553.7 4,468.8 3,925.3 
Oncology:
Verzenio®
1,653.2 834.9 618.2 830.3 515.0 294.4 
Cyramza®
351.4 358.1 381.9 620.0 674.8 650.8 
Alimta®
543.7 1,233.9 1,265.3 384.0 827.5 1,064.7 
Erbitux®
500.1 481.8 480.1 66.4 66.4 56.3 
Tyvyt®
— — — 293.3 418.1 308.7 
Other oncology169.7 120.1 46.6 254.1 210.7 152.3 
Total oncology3,218.1 3,028.8 2,792.1 2,448.1 2,712.5 2,527.2 
Immunology:
Taltz®
1,724.6 1,542.4 1,288.5 757.4 670.4 500.0 
Olumiant® (3)
148.2 324.1 63.8 682.3 791.0 575.0 
Other immunology20.0 15.3 20.0 12.1 17.6 14.6 
Total immunology1,892.8 1,881.8 1,372.3 1,451.8 1,479.0 1,089.6 
Neuroscience:
Emgality®
462.8 434.5 325.9 188.1 142.7 37.0 
Zyprexa®
30.4 39.6 46.1 306.5 390.7 360.5 
Cymbalta®
33.7 38.7 42.1 249.6 542.8 725.6 
Other neuroscience85.5 102.0 73.2 189.6 207.5 220.9 
Total neuroscience612.4 614.8 487.3 933.8 1,283.7 1,344.0 
Other:
COVID-19 antibodies(4)
2,008.9 1,978.0 850.0 14.7 261.4 21.2 
Forteo®
367.3 441.6 510.3 245.8 360.3 536.0 
Cialis®
35.2 10.6 61.8 552.1 707.9 545.4 
Other144.2 136.1 246.4 151.3 233.9 321.8 
Total other2,555.7 2,566.4 1,668.4 964.0 1,563.5 1,424.4 
Revenue$18,190.0 $16,811.0 $14,229.3 $10,351.3 $11,507.4 $10,310.5 
Numbers may not add due to rounding.
(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(2) Humalog revenue includes insulin lispro.
(3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
202220212020
Revenue—to unaffiliated customers(1):
U.S.$18,190.0 $16,811.0 $14,229.3 
Europe4,299.2 4,776.8 4,187.7 
Japan1,747.3 2,367.0 2,583.1 
China1,452.8 1,661.4 1,116.9 
Other foreign countries2,852.0 2,702.2 2,422.7 
Revenue$28,541.4 $28,318.4 $24,539.8 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer
Schedule of Amounts Recorded for Contract Liabilities
The following table summarizes contract liability balances:
 20222021
Contract liabilities$219.2 $262.6